A biologic definition of Burkitt's lymphoma from transcriptional and genomic profiling.
By M. Hummel, S. Bentink, Hilmar Berger, W. Klapper, S. Wessendorf, T. Barth, H. Bernd, S. Cogliatti, J. Dierlamm, A. Feller and 25 more. New England Journal of Medicine, 2006
1,102 citations recorded by the source corpus.
Subfields: Dermatology, Neurology, Pathology and Forensic Medicine
View Paper: https://www.semanticscholar.org/paper/265896576572e3f15b45177577ea8ff7ead7c7b1
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Pathology and Forensic Medicine
Citations in the corpus
- Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways (2008, background): “Moreover, the distinction between ABC and GCB DLBCL has been associated with the response to chemotherapy in several large cohorts of patients (3, 4, 31).”
- PrognoScan: a new database for meta-analysis of the prognostic value of genes (2009, background): “As of February 2009, the collection included more than 40 datasets of various cancer types spanning a wide range of cancers including bladder, blood, breast, brain, esophagus, head and neck, kidney, lung, and ovarian (Table 1) [ 10-35 ], far more comprehensive than both ITTACA, which focuses on blad”
- The 2016 revision of the World Health Organization classification of lymphoid neoplasms. (2016, neutral): “Lymphomas with a GEP intermediate between that of molecular BL and molecular non-BL (mostly DLBCL), also lends support to the existence of these intermediate-type cases, which were not, however, considered a specific entity.(84,85) Segregation of these cases was also necessary to better define these”
- The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. (2011, background): “Biologically and clinically, they are distinct from both conventional DLBCL and BL.”
- Stromal Gene Signatures in Large-B-Cell Lymphomas (2008, neutral): “4 or 5 24/182 (13) 10/85 (12) 11/71 (15) 3/26 (12)”
- The 2008 WHO classification of lymphomas: implications for clinical practice and translational research (2009, neutral): “Diffuse areas in any Grade 3 FL should be designated as DLBCL (with FL) and are more commonly observed in Grade 3B.62 Further studies are likely to lead to more precise delineation of the Grade 3 cases truly belonging within FL and those representing an intrafollicular variant of the GCB type of DLB”